RYONCIL® PRODUCT INFORMATION NOW AVAILABLE IN ALL FOURMAJOR DRUG PRICING COMPENDIA IN UNITED STATESMelbourne, Australia; March 14 and New York, USA; March 13, 2025:
Mesoblast Limited(ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases,today announced that pricing information for Ryoncil® is now available in all four major drug pricingcompendia in the United States. These pricing compendia provide the official source for all informationrequired to order product, including product manufacturing details, National Drug Codes (NDC) for kitpurchase, and kit pricing.
The pricing compendia listing followed approval and publication by the U.S. Food and DrugAdministration (FDA) of the revised Ryoncil® label, which includes revisions to Section 16 (How Supplied/ Storage and Handling) of the product prescribing information. The revisions included acceptance ofeight new Ryoncil® kits, each with its own NDC, based on allocation of product dosage according topatient weight-bands. Treatment centers will be able to order kits tailored to the appropriate dosage foreach patient, with pricing applied uniformly, regardless of patient weight.
The four compendia comprise Merative Micromedex® RED BOOK®, First Databank FDB MedKnowledge®Drug Pricing, Elsevier Gold Standard Drug Database, and Wolters Kluwer Medi-Span® Price Rx®
MSB Price at posting:
$2.08 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)